Q2 FY26 results: revenue up, NCD redemption, BBL CCD purchase

Exceptional ItemResults View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹387.00

prior close

₹387.50

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.8%+3.9% vs market

Pharmaceuticals peers, median of 157sector+0.8%+3.9% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Midcap 150 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+0.9

15m

+0.2

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+0.8+3.9+0.8+3.9

Next day

+7.6+0.4+7.2+0.5+7.1

+6.3+0.5+5.8+0.4+6.0

+9.3+1.2+8.1+0.4+8.8

+8.9+0.5+8.4-0.1+9.1

+5.9+0.9+5.0-0.6+6.5

+2.7-0.3+3.0-1.2+3.9

15d

+6.1-0.4+6.5-1.8+7.9

-0.4-0.3-0.1-2.6+2.2

-4.2-1.2-2.9-5.4+1.2

-2.8+0.1-2.9-6.0+3.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2/H1 FY26 results. Consol revenue from ops Rs 4,296 crore (up about 20% YoY), consol PAT Rs 91 crore. Also cleared early redemption of 50,000 NCDs worth Rs 500 crore, purchase of BBL CCDs from Edelweiss for Rs 300 crore (raises BBL stake by about 65 bps), and issuance of commercial papers up to Rs 550 crore. Limited review report is unqualified.

Likely market impact

Revenue growth and active debt restructuring via QIP proceeds show deleveraging focus. Higher BBL stake consolidates biologics subsidiary.